Polar Capital Holdings’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Polar Capital Holdings’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,762	Closed	-$235K	–	314
2023 Q3	$235K	Sell	10,762 -900,000	-99%	-$22.5M	﹤0.01%	274
2023 Q2	$29M	Buy	910,762 +142,486	+19%	+$4.37M	0.15%	124
2023 Q1	$18.7M	Buy	768,276 +296,961	+63%	+$8.72M	0.12%	144
2022 Q4	$14.9M	Sell	471,315 -46,961	-9%	-$1.33M	0.12%	169
2022 Q3	$14.6K	Buy	518,276 +18,276	+4%	+$544K	0.09%	163
2022 Q2	$13.2K	Sell	500,000 -250,000	-33%	-$7.1M	0.08%	176
2022 Q1	$26.3K	Hold	750,000	–	–	0.12%	144
2021 Q4	$24.3K	Hold	750,000	–	–	0.09%	154
2021 Q3	$22.1K	Buy	750,000 +700,000	+1,400%	+$19.7M	0.09%	162
2021 Q2	$1.28K	Buy	+50,000	New	+$716K	0.01%	317

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Polar Capital Holdings's CERE Position: Q4 2023 in Review

Polar Capital Holdings sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023, closing a stake of 10,762 shares — an estimated $235K sold.

Polar Capital Holdings first reported a position in CERE in Q2 2021 and held it in 10 quarters. The position peaked at $29M in Q2 2023. 195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

Polar Capital Holdings reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Polar Capital Holdings sold 10,762 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2023, an estimated $235K.
Polar Capital Holdings first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Polar Capital Holdings's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $29M in Q2 2023.
195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on Polar Capital Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.